Cell line · CVCL_0313
HPAF-II
Cancer cell line, Homo sapiens. Pancreatic ductal adenocarcinoma. 83 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. HPAF-II. Cell lines, record CVCL_0313. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0313
On this page
Cell line
As Cellosaurus gives it.
- Name
- HPAF-II
- Accession
- CVCL_0313
- RRID
- RRID:CVCL_0313
- Synonyms
- HPAF II, HPAFII, HPAF-2, HPAF2, HPAF/CD18, CD18/HPAF, HPAF-II/CD18, CD-18, CD18, CD 18
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 44Y
- Category
- Cancer cell line
- Diseases
- Pancreatic ductal adenocarcinoma (NCIt C9120)
- Derived from
- Ascites (metastatic)
- Parent
- HPAF (CVCL_B284)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems2
| Problem | Cellosaurus's note |
|---|---|
| Caution | Could not find proof that the CD18 subline of HPAF is really HPAF-II but many indirect evidences points in this direction. If someone read this comment and can help us, please do. |
| Caution | TP53 mutation indicated incorrectly as being at c.452C>T in PubMed=1764370. |
Source Cellosaurus
Papers83
3 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADCE-T02: A Next-generation Antibody-Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 83
See all 83 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Parent | HPAF | CVCL_B284 |
Source Cell lines
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1997 | ATCC | |
| CLS | 305088 | CLS | |
| IZSLER | BS TCL 170 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0313
GET https://conductscience.org/api/cell-lines/v1/CVCL_0313/papers?page=2